Dr Ken Taylor
Professor Carolyn Sue AM
Dr Andrew Kelly
Professor Bernie Tuch
Professor Tuch is an Honorary Professor at The University of Sydney where he is supervising a bioengineering diabetes cell therapy project. Previously, he was a senior scientist with CSIRO Australia. He is a director of Sydney Cell Therapy Foundation Pty Limited, the not-for-profit Australian Foundation for Diabetes Research, and is a Specialist Practitioner, Endocrinology, at the Prince of Wales Private Hospital & St Vincent’s Private Hospital, Sydney. He is also an Adjunct Professor at Monash University.
His experience includes capital raising to support his considerable research team and a large international scientific publication list. He has had previous scientific collaborations with LCT and knows the company’s direction intimately.
Professor Tuch is chairman of the Remuneration and Nomination Committee. He was appointed to the board on 20 July 2011 and appointed interim chairman on 31 August 2018.
Dr Ken Taylor
Dr Taylor has had a prestigious international career in both academia and business. He completed a postdoctoral fellowship in Pharmacology and Experimental Therapeutics at the Johns Hopkins University School of Medicine in Maryland, USA, and subsequently held a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical Research in Princeton, New Jersey. He joined Roche Australia and was soon promoted to the role of Medical Director, Australia, before becoming Managing Director of Roche New Zealand. In 1990, Ken was appointed Managing Director of the Roche UK affiliate and then transferred to Syntex in Palo Alto, California to convert the corporate pharmaceutical company to the Roche Bioscience Research Center.
Prior to joining LCT, Dr Taylor was CEO of Antipodean Pharmaceuticals where he managed the Phase I and II studies of its lead compound in Parkinson’s disease.
New Zealand-born Dr Taylor holds Honours and Doctorate degrees in pharmaceutical chemistry and pharmacology from the University of Otago School of Medicine and completed a business management program at IMD in Lausanne, Switzerland.
Ken joined LCT in February 2014 and was appointed to the board on 31 August 2018.
Sir Robert Elliott trained as a paediatrician at Adelaide University. He moved to New Zealand in 1970 to become the Foundation Professor, Director of Paediatrics at The University of Auckland. Sir Robert co‑founded LCT. He is an Emeritus Professor of Child Health Research and a world leader in diabetes and autoimmune related research. He resigned from the position of Director, Clinical Research and Innovation on 27 February 2015.
Sir Robert received his knighthood in June 2020 for services to medical research. In 2011 he was awarded the prestigious World Class New Zealander (Life Sciences) award.In 1999 he was awarded a CNZM (a Companion of the New Zealand Order of Merit) for services to the community.
He is on the board of Cure Kids and patron of the NZ Cystic Fibrosis Foundation. He is a director and shareholder of Breathe Easy Limited, Kopu Limited, Visregen Technologies Limited, Fac8 Limited and NZeno Limited.
Sir Robert resigned as Chairman of the Diatranz Otsuka Limited board of directors in January 2018. He was appointed to LCT board on 15 January 2004.
Robert Willcocks is a senior executive with an extensive legal and business background working in particular with Australian listed public companies. He has Bachelor of Arts and Bachelor of Laws degrees from the Australian National University and a Master of Laws degree from the University of Sydney. Mr Willcocks was a partner with the law firm Stephen Jaques & Stephen (now King & Wood Mallesons) from 1980 until 1994, where he was a member of the Corporate Advisory Group with an emphasis on the mining and oil and gas sectors. As corporate adviser he has undertaken assignments in a range of industry sectors.
Mr Willcocks has been a director and Chairman of a number of Australian Securities Exchange (ASX) listed public companies. He is a former director of ASX listed ARC Exploration Limited, and Hong Kong Stock Exchange listed APAC Resources Ltd. He is also chairman and director of Trilogy Funds Management Ltd, a Responsible Entity under Australian law.
Mr Willcocks is chairman of the Audit and Compliance Committee and a member of the Remuneration and Nomination Committee.
He was appointed to the board on 29 March 2011.
Professor Carolyn Sue AM
Dr Sue has an extensive background in neurological science and medicine in relation to chronic illnesses. She is the Head of Neuroscience Research at the Kolling Institute at Sydney’s Royal North Shore Hospital, and Director of Neurogenetics, Director of the National Centre for Adult Stem Cell Research and a Senior Staff Specialist in the Department of Neurology at the Kolling Institute. She holds a M.B., B.S. from the University of New South Wales and a PhD from the University of Sydney and is a Professor at Sydney Medical School. She is also a Fellow of the Royal Australasian College of Physicians (FRACP) and an officer of the Asian-Oceanic Section of the International Movement Disorder Society.
Professor Sue was recognised as a Member in the General Division of the Order of Australia in the 2019 Queen's Birthday honours for her service to medicine.
Professor Sue was appointed to the board on 16 May 2019.
Dr Andrew Kelly
Andrew Kelly has an extensive background in research, commercialisation and investment. In 2005 he co-founded BioPacificVentures, the first specialist venture fund in New Zealand and Australia to focus across the life sciences. In 2014 he broadened the business model to create BioPacific Partners, partnering with some of the largest global companies to invest and engage with local innovation. He has held a dozen board roles over the last 22 years all in businesses involved in life science innovation. Dr Kelly has strong networks across New Zealand and Australia and globally.
Dr Kelly spent the early part of his career in life sciences research and development in Australia and Canada and then led research institutes in Australia and New Zealand. He later led product development and then early stage investment at AgResearch. In this role he built deep engagement with the global investor community.
Dr Kelly was appointed to the board on 7 November 2019.
Mark Licciardo is the founder and managing director of Mertons Corporate Services. He has extensive experience in working with Boards of Directors of high profile ASX listed companies in the areas of corporate governance, accounting & finance and company secretarial practices during a 30 year corporate career in banking and finance, funds management, investment, infrastructure development and in the establishment and management of a consulting business. A former company secretary of Top 50 ASX listed companies Transurban Group and Australian Foundation Investment Company Limited, Mark is also the former Chairman of the Governance Institute of Australia (GIA) Victoria division and Melbourne Fringe Festival and a current non-executive director of a number of public and private companies.